Emergence of macrolide-resistant *Bordetella pertussis* in France, 2024: out of China

Valérie Bouchez, Ph.D. ORCID 0000-0002-5947-6383

Institut Pasteur, Paris, France

Noémie Lefrancq, Ph.D. ORCID 0000-0001-5991-6169

Eidgenössische Technische Hochschule (ETH), Zurich, Switzerland

Julie Toubiana, MD, Ph.D. ORCID 0000-0001-9561-669X

Institut Pasteur, Paris, France

Carla Rodrigues PharmD., Ph.D.* ORCID 0000-0002-9608-2404

Institut Pasteur, Paris, France

Sylvain Brisse, Ph.D.* ORCID 0000-0002-2516-2108

Institut Pasteur, Paris, France

**Co-supervised the work*

Correspondence: Prof Sylvain Brisse, sylvain.brisse@pasteur.fr
Institut Pasteur, Université Paris Cité, Biodiversity and Epidemiology of Bacterial Pathogens, National Reference Center for Whooping cough and other Bordetella infections, Institut Pasteur, 25-28 rue du Docteur Roux, 75724 Paris Cedex 15, FRANCE
Tel : 33 (0)1 45 68 83 34

ABSTRACT

Pertussis is a highly contagious vaccine-preventable respiratory disease, primarily caused by *Bordetella pertussis* (*Bp*). Macrolides constitute the first-line treatment for pertussis, reducing bacterial carriage and transmission. Macrolide-resistant *Bp* (MRBP) isolates have been reported in China since 2011. Here, we report 14 MRBP cases from France collected between February and November 2024. Phylogenetic analysis based on whole-genome single nucleotide polymorphisms revealed that the 14 isolates belong to a cluster of 349 MRBP isolates, of genotype *ptxP3*, and form three separate branches nested within the diversity of isolates from China. These data suggest three independent introductions into France. Two of these branches were detected across several French administrative regions, suggesting forward transmission and spatial dissemination. The *ptxP3*-MRBP clade emerged in China only around 2016 and became predominant after 2020. Its dissemination in France in 2024 is consistent with a high predicted fitness of the ptxP3 genotype in countries using acellular vaccines.

FULL TEXT

Pertussis is a highly contagious vaccine-preventable respiratory disease, primarily caused by *B. pertussis* (*Bp*), that can be lethal in young infants. In 2024, an intense post-COVID19 resurgence of pertussis has occurred in Europe and elsewhere (1).

Macrolides constitute the first-line treatment for pertussis, reducing bacterial carriage and transmission. Of major public health concern, macrolide-resistant *Bp* (MRBP) isolates have been reported in China since 2011, now reaching > 90% in some settings . Elsewhere, only sporadic MRBP cases have been reported up to now, including one case in France in 2011 . MRBP isolates belong to two main phylogenetic clades, *ptxP1* and *ptxP3*, differing by a mutation in the promoter of the pertussis toxin (*ptx*P) gene cluster (3,4).

Here, we report 14 MRBP cases from France collected between February and November 2024, (among 345 cultivated *B. pertussis* isolates from 2024; Table S1). These MRBP isolates (hereafter referred to as "the study isolates") carried the A2047G mutation in the 3 copies of the *23S rRNA* gene, concordant with their antimicrobial resistance phenotype. To investigate whether the study isolates arose from macrolide-susceptible *Bp* (MSBP) in France or were imported, we compared their genomic sequences with 1,572 *Bp* collected in France (1993-2024, including the MRBP from 2011), and 824 *Bp* collected in China (2018-2024; NCBI BioProjects PRJNA908268 and PRJNA1071282), including 596 MRBP (75.2%) (3,4). Phylogenetic analysis based on whole-genome single nucleotide polymorphisms (Figure 1) revealed that the study isolates belong to a cluster of 349 MRBP isolates (Figure 1B; the *ptxP3*-MRBP clade), and form three separate branches nested within the diversity of isolates from China, suggesting three independent introductions into France. Two of these branches comprised more than one isolate, detected across several French administrative regions, suggesting forward transmission and spatial dissemination (Figure 1C).

The rise of MRBP in France in 2024 is exceptional and concerning. While these data suggest three direct introductions from China to France, cryptic transmission through intermediary unsampled countries cannot be excluded. More globally representative sampling and genomic analyses are needed to shed light on *Bp* global spread. Understanding the impact of global mobility versus local transmission on the emergence of MRBP is crucial for defining effective strategies to control macrolide-resistant pertussis. Although they emerged 15 years ago in China, MRBP are only emerging in France in 2024, despite disease activity in 2010-2019 (1). As MRBP initially emerged in China within the *ptxP1* branch, we propose that this surprising delay might be due to the lower fitness of *ptxP1* isolates in acellular vaccination countries. The *ptxP3*-MRBP clade emerged in China only around 2016 and became predominant after 2020 (3,4). Its dissemination in France in 2024 is consistent with its high predicted fitness. Effective control of MRBP will require enhanced surveillance, strict adherence to transmission control guidelines, and prudent use of macrolides to treat pertussis and other infections in order to avoid selective pressure favoring MRBP. Defining effective alternative treatments, particularly for newborns, is essential for the clinical management of future macrolide-resistant cases (2).

Figure 1. Phylogenetic diversity and geographic dissemination of macrolide-resistant Bordetella pertussis, France 2024.

Figure 1 legend

The tree was constructed based on whole genome SNPs using method described in Lefrancq *et al*. **Panel A** presents the tree obtained from the whole dataset: tree leaves are red for MRBP, (allele 13, *i.e.*, 23S rRNA A2047G mutation) or green for MSBP (allele 1); 2 isolates with a single mutated copy of the *23S rRNA* gene are colored in orange. Landmark mutation *ptxP3* is indicated at corresponding node with a black triangle. The columns indicate the country of origin (France: dark blue; China: light blue); years of collection (from 1975 to 2024), *ptxP* and *fim3* alleles (light purple for allele 1, darker purple for alleles *fim3*-2 and *ptxP3*, light grey for other or undefined

alleles). The scales indicate the number of SNPs per genome. **Panel B** focuses on the emerging *ptxP3*-MRBP clade (349 isolates). Evolved SNPs shared by this clade at the black star location are detailed in the Supplementary Appendix, Table S2; the 23S rRNA mutation is indicated by a red star; a pertactin-inactivating mutation by a lightning symbol. The pertactin-negative subclade was introduced twice into France. The three introductions of MRBP into France are labelled as I1, I2 and I3 and highlighted by light grey horizontal bars (see Table S3 for details). **Panel C** presents the detailed trees of the three introductions of MRBP into France, and their geographic origins, as indicated in the map colored according to French administrative regions: orange for 'Grand Est' (GES), purple for 'Ile de France' (IDF), green for 'Auvergne Rhône Alpes' (ARA) and salmon for 'Nouvelle Aquitaine' (NAQ). Circles at branch tips are colored according to country (light blue: China; darker blue: France).

The tree can be interactively visualized in Microreact (**https://microreact.org/project/5mvNLVqAoPoT2V6y2kUPFw-bp-cnr-china-all**).

References

1. Rodrigues C, Bouchez V, Soares A, Trombert-Paolantoni S, Aït El Belghiti F, Cohen JF, et al. Resurgence of Bordetella pertussis, including one macrolide-resistant isolate, France, 2024. Euro Surveill. août 2024;29(31).
2. Ivaska L, Barkoff AM, Mertsola J, He Q. Macrolide Resistance in Bordetella pertussis: Current Situation and Future Challenges. Antibiotics (Basel). 7 nov 2022;11(11).
3. Fu P, Yan G, Li Y, Xie L, Ke Y, Qiu S, et al. Pertussis upsurge, age shift and vaccine escape post-COVID-19 caused by ptxP3 macrolide-resistant Bordetella pertussis MT28 clone in China. Clin Microbiol Infect. nov 2024;30(11):1439–46.
4. Cai J, Chen M, Liu Q, Luo J, Yuan L, Chen Y, et al. Domination of an emerging erythromycin-resistant ptxP3 Bordetella pertussis clone in Shanghai, China. Int J Antimicrob Agents. juill 2023;62(1):106835.
5. Lefrancq N, Bouchez V, Fernandes N, Barkoff AM, Bosch T, Dalby T, et al. Global spatial dynamics and vaccine-induced fitness changes of Bordetella pertussis. Sci Transl Med. 27 avr 2022;14(642):eabn3253.

Ethical statement

Phenotypic and genotypic analyses of bacterial isolates were carried out within the framework of the mandate given to the National Reference Center for Whooping Cough and Other Bordetella Infections by the Ministry of Health (Public Health France). All French bacteriological samples

and data were collected in the frame of the French national diphtheria surveillance and are collected, coded, shipped, managed and analyzed according to the French National Reference Center protocols that received approval by French supervisory ethics authority (CNIL No. 1474593). Other strains and genomic sequences were obtained from culture collections and from public repositories.

Funding

The National Reference Center for Whooping Cough and Other Bordetella Infections receives support from Institut Pasteur and Public Health France (Santé publique France, Saint Maurice, France). No specific funding was received for this study, as it was performed within the frame of the French national surveillance of whooping cough.


A
20 subs.
Country
Year
ptxP
fim3
ptxP3
B
ptxP3-MRBP
3 subs.
Country
ptxP
fim3
I1
I2
I3
23S
1
1 and 13
13
Country
China
France
Year
<1975
2010
2024
ptxP
1
3
Others
fim3
1
2
Others
C
Introductions
Regions
I2
Regions
GES
IDF
ARA
NAQ
Regions
I3
1 sub.
Regions
I1